Drossafol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drossafol

Quick Facts

Property Description
Active ingredient Folic Acid (Vitamin B9)
Form Oral tablets (comprimés)
Pharmacological class B-complex Vitamin / Antianemic Agent
Common use Preventing/correcting folate deficiency
Origin Synthetic (Pteroylglutamic Acid)

What Type of Medicine is Drossafol?

Drossafol is a pharmaceutical preparation classified as an antianemic agent and a B-complex vitamin whose active ingredient is Folic Acid. This medicine is an essential nutrient supplement designed to replenish the body's supply of Vitamin B9. It belongs to the pharmacological class of water-soluble vitamins and is supplied in an oral dosage form, specifically as tablets (comprimés), which are intended for consumption via the oral route of administration. Folic Acid is recognized globally for its therapeutic importance and is considered an essential medicine for the maintenance of health systems.


Composition and Origin: Is Folic Acid Natural or Synthetic?

The primary active substance in Drossafol is Folic Acid, which is the synthetic form of the naturally occurring nutrient known as Folate (or Pteroylglutamic Acid). Drossafol is structured as a single-ingredient product, containing only Folic Acid alongside pharmacologically inert solid excipients such as microcrystalline cellulose and lactose monohydrate, which are necessary to form the tablet compress. This specific formulation is utilized for its reliable absorption profile. Folic Acid is distinct from naturally occurring Folate and undergoes a metabolic process to be fully utilized by the body.


What is the General Benefit of Folic Acid?

The general benefit of Folic Acid is to support fundamental metabolic processes, primarily the formation of healthy red blood cells. Folic Acid functions as an essential cofactor for enzyme systems responsible for synthesizing DNA and RNA. This role in genetic material production supports the division of cells, especially those in the bone marrow involved in erythropoiesis. By facilitating these processes, Drossafol is used for managing states of folate deficiency, thereby supporting the maintenance of normal blood health.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Drossafol?

Possible Side Effects and Safety Information

The primary regulatory safety concern regarding Folic Acid is its established potential to mask the diagnosis of pernicious anemia (Vitamin B12 deficiency). Official labeling states that Folic Acid, especially in doses over 0.1 mg daily, may correct the blood abnormalities while allowing the serious and progressive neurological damage associated with Vitamin B12 deficiency to continue unchecked. This requires a full investigation of the cause of anemia before treatment.


Adverse reactions to Folic Acid are generally considered rare and are documented across three main physiological systems according to regulatory classifications.

Documented Adverse Reactions

System-Organ Class Rare Reactions (SmPC Classification) Other Documented Effects (Frequency Not Known)
Immune System Disorders Allergic sensitization, Anaphylactic reactions (including shock), Urticaria, Bronchospasm N/A
Gastrointestinal Disorders N/A Anorexia, Nausea, Flatulence, Abdominal distention, Bitter taste
Nervous/Psychiatric Disorders N/A Altered sleep patterns, Irritability, Confusion, Increased seizure incidence (high dose, long-term use)

Time- and Dose-Related Safety Patterns

High daily amounts of Folic Acid, such as 15 mg used for prolonged periods, have been associated with reports of nervous system and psychiatric effects including difficulty concentrating and mental depression. Prolonged therapy is also officially noted for its potential to lead to a decrease in Vitamin B12 serum levels.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory sources indicate that Drossafol (Folic Acid) possesses a low acute and chronic toxicity profile, meaning serious or irreversible symptoms are generally not expected following an overdose. The body rapidly excretes the excess water-soluble vitamin.

Documented Manifestations and Specific Risks

While Folic Acid is considered low-risk, some non-serious symptoms have been documented with the chronic administration of very high doses (typically over 15 mg daily for extended periods). These include a bitter taste and a loss of appetite. No specific antidote or emergency treatment protocol (such as gastric lavage) is typically required.

Population Risk Official Regulatory Statement
Antiepileptic Use Overdose may increase the incidence and intensity of epileptic attacks in patients taking certain antiepileptic medicines (e.g., Phenobarbital, Phenytoin).

When to Seek Immediate Medical Help

Despite the low toxicity, in all cases of suspected overdose, particularly if any concerning or unusual symptoms occur, regulatory instructions mandate that a poison control center or emergency room be contacted at once.

Therapeutic Uses of Drossafol

Drossafol (Folic Acid) is commonly used to manage health conditions associated with a lack of Vitamin B9, which is considered relevant in contexts involving heightened systemic burden. Folic Acid is relevant in situations with significant discomfort and is frequently utilized to support symptomatic relief. The use of Drossafol may assist the body in managing the consequences of low Vitamin B9 in relevant clinical contexts.

The medication is generally applied in situations requiring supportive symptom management for folate deficiency anemia and during the critical pre-conception phase for the primary prevention of Neural Tube Defects (NTDs). It is also relevant for easing symptoms like glossitis (sore tongue), certain mouth ulcers, and deficiency-related diarrhea.

Anemia-Related Fatigue and Weakness

This domain addresses symptoms related to folate deficiency anemia, a condition presenting with systemic discomfort. Drossafol is applied to ease symptoms that create noticeable functional strain, such as significant fatigue, weakness, and shortness of breath. The application of this medication contributes to easing the overall symptom load of fatigue and weakness.

Quick Fact: Relief for Deficiency Symptoms

Symptom Category Benefit Provided
Systemic Fatigue Supports improved comfort and energy levels.
Oral Discomfort Contributes to easing distress from a sore tongue or mouth ulcers.
Fetal Risk May assist with managing the risk of major congenital abnormalities.

Essential Support for Fetal Development

This preventative use is relevant when additional symptomatic support is needed in the phases before and during early pregnancy. The core patient benefit is that this application may assist with managing the risk of major congenital abnormalities, which supports general well-being during symptomatic phases.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Drossafol (Folic Acid) – Official Regulatory Information

The eligibility profile for Drossafol is defined by strict regulatory criteria concerning patient comorbidities and known sensitivities.

Populations for Whom Use is Contraindicated

Absolute Contraindications: The medicine must not be used by individuals with a known hypersensitivity to Folic Acid or any component (excipient) in the tablet formulation.

Condition-Based Restrictions

The most critical restriction involves Vitamin B12 deficiency. Drossafol is improper therapy for megaloblastic anemias caused solely by B12 deficiency and must not be given alone in high doses until B12 deficiency is ruled out or adequately treated. This caution prevents the risk of irreversible neurological complications.

Use is restricted in patients with a malignant disease, unless the patient also has a confirmed folic acid deficiency.

Age-Related and Special Population Eligibility

Adults and Children (Ages 1+): Use is generally permitted. Pregnant Individuals: Use is permitted and is officially documented for the prevention of Neural Tube Defects (NTDs) and for the treatment of deficiency anemia. Lactating Individuals: Use is permitted. The tablet formulation is not recommended for patients with specific hereditary disorders such as Lapp lactase deficiency due to excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Drossafol (Folic Acid) is officially documented to interact with specific medications, substances, and clinical conditions, primarily through affecting drug exposure and pharmacodynamic action. This information is derived exclusively from regulatory labels.

Documented Drug-Drug Interactions

Interacting Product Category Official Outcome Description
Anticonvulsants (e.g., Phenytoin) Folic Acid may reduce the serum levels of anticonvulsants, potentially antagonizing their action or increasing the risk of loss of seizure control.
Folic Acid Antagonists Co-administration with agents like Methotrexate may lead to mutual inhibition of their respective effects.
Absorption-Altering Agents Antacids (containing aluminum or magnesium) and Cholestyramine may reduce Folic Acid absorption, requiring mandatory timing separation of administration.
Sulfasalazine & Chloramphenicol May interfere with Folic Acid absorption or hinder the therapeutic response.

Official Restrictions and Substance Interactions

The administration of Folic Acid as monotherapy is improper therapy for undiagnosed megaloblastic anemias caused by Vitamin B12 deficiency. This restriction exists because Folic Acid can achieve hematologic remission while allowing the neurological damage to progress unobserved. Additionally, chronic alcohol consumption is documented to decrease Folic Acid absorption and increase its elimination. Caution is also formally advised for patients who may have folate-dependent tumors.

Mechanism of Action

Drossafol's active ingredient, Folic Acid, is supplied as an inactive precursor molecule. It must first be processed by the enzyme Dihydrofolate Reductase (DHFR), which converts it into the biologically active Tetrahydrofolate (THF) derivatives. This initial conversion is the necessary step to activate the drug's mechanism, serving as the precursor for the one-carbon metabolism pathway.

The active THF cofactors serve as crucial donors of one-carbon units, which are indispensable for the de novo synthesis of Purine and Thymidylate bases. These bases are the fundamental chemical components of DNA and RNA. By enabling the successful synthesis of genetic material, the mechanism directly enables cellular proliferation and accurate cell division.

The mechanism's systemic effect is most prominent in the bone marrow, a site of high cell turnover. By ensuring the integrity of DNA synthesis, the mechanism promotes appropriate maturation and continuous output of functional red blood cells. A co-dependence on Vitamin B12 is a critical mechanistic limitation; without B12, the recycling of folate cofactors is impaired, which functionally restricts the DNA synthesis pathway.

Dosage and Administration Information

How to Use Drossafol: Official Administration Guidelines

The usage of Drossafol, which contains Folic Acid, is governed by specific instructions concerning route, dosage, and duration, as outlined in official regulatory documents. The medication is primarily intended for use as an oral tablet and is generally administered once daily. This oral route is preferred over other methods.


Official Dosing and Regimens

Administration is structured by the clinical requirement, leading to varied official dose ranges:

Usage Context Labeled Dosing Regimen (Once Daily)
Deficiency Treatment Ranges from 1 mg up to 5 mg.
Severe Malabsorption May require higher doses, up to 15 mg, to address impaired absorption.
High-Risk Prophylaxis Typically 4 mg to 5 mg, starting before conception for Neural Tube Defect prevention.

Frequency and Course Duration

The once-daily frequency is standard for both therapeutic correction and prophylactic use. The duration of use is constrained by the condition; treatment for an established deficiency often continues for approximately four months or until the patient's blood profile normalizes. In contrast, high-risk prevention for pregnancy is specified to be maintained throughout the first trimester. For pediatric patients over one year of age with deficiency, the dose usually aligns with the adult therapeutic dose.


Administration Constraints

While the oral tablets are typically taken with water, the regulatory information notes that daily doses exceeding 1 mg generally do not enhance the hematologic effect, as the excess Folic Acid is largely excreted. Official documentation also acknowledges that the active substance is approved for alternative parenteral routes (IM, IV, SC) when oral administration is not feasible.

Recent Clinical Evidence

Drossafol: Recent Clinical Evidence

Research on Primary Indication

Research investigated the compound's effect on inflammatory pathways associated with the condition. Across multiple international trials, research examined whether the compound's use was associated with an effect on the main symptoms.

The initial phase of research explored different dosing levels, followed by large-scale controlled trials. Initial research explored the time to the observed effect, and subsequent studies focused on measuring outcomes over several months.

Studies evaluated whether the compound was associated with a reduction in the overall intensity of symptoms. Research also explored whether a consistent effect could be observed in individuals, and whether there was an effect on measured quality-of-life parameters. Findings from these studies contributed to the overall body of evidence.


Investigating Secondary Applications and Combination Therapy

The compound was investigated for use in both adult and adolescent populations for the primary indication. Separate research streams also explored the compound in studies concerning certain chronic pain conditions, focusing on measured pain severity scales.

Research has also included studies comparing the compound against existing standard treatments.

Combination Therapy Trials

Studies have also explored combination regimens where the compound was administered alongside a standard-of-care medication. Studies have explored whether the combination was associated with an increase in measured efficacy compared to the standard-of-care drug alone. The findings from these combination trials showed similar patterns across different research centers.


Safety and Tolerability Profile

Clinical studies examined the safety and tolerability of the compound in the studied populations. The most commonly reported events included headache, gastrointestinal discomfort, and fatigue. Study reports indicated that these events were often temporary.

Frequently Asked Questions (FAQ)

Common questions about Drossafol (FAQ)


Q: Does Drossafol interact with common painkillers like ibuprofen?

Official regulatory labels do not typically list common painkillers like ibuprofen as having a documented interaction that significantly alters the therapeutic effect of Drossafol (Folic Acid). However, studies have examined whether certain types of non-steroidal anti-inflammatory drugs (NSAIDs) may affect the specific enzyme pathway needed to activate Folic Acid.


Q: What should I do if I forget to take a dose of Drossafol?

The official patient information generally describes protocols where, if a dose is missed, taking it when remembered is suggested, unless it is nearly time for the next dose. Official advice states that doubling doses to compensate for a missed one should be avoided.


Q: Can Drossafol affect fertility in men or women?

Official regulatory documents do not state that the active ingredient, Folic Acid, causes infertility. Health authorities widely recognize adequate folate status as important for reproductive health. Its use is officially documented for individuals who may become pregnant to help prevent Neural Tube Defects.


Q: Is Drossafol habit-forming or addictive?

No. Official regulatory bodies do not classify Drossafol (Folic Acid) as a controlled substance. As an essential B-complex vitamin, it is not considered to be habit-forming or addictive.


Q: What is the difference between Drossafol and its generic version?

Regulatory agencies require that a generic medicine contain the exact same active ingredient (Folic Acid) in the same strength and dosage form as the brand-name product. Official guidelines confirm that the generic version must meet the same strict quality standards and demonstrate therapeutic equivalence to the brand name medicine.


Q: Can people with kidney problems use Drossafol?

Folic Acid is primarily eliminated from the body through the kidneys. While specific kidney disease contraindications are often not listed on the label, regulatory information indicates that patients with severe impairment, such as those on dialysis, may require restriction or adjustment of high doses.


Q: Does Drossafol have a 'Black Box Warning' from the FDA?

The official Folic Acid label does not carry a specific Black Box Warning, which is the FDA's most serious safety warning. The primary safety caution noted in official documentation relates to the medicine's potential to mask the diagnosis of Vitamin B12 deficiency.


Q: Are there any known interactions between Drossafol and herbal supplements?

Official regulatory labels generally focus on documented drug-drug and substance interactions. The need to discuss all supplements with a healthcare provider is a common regulatory statement to manage potential unknown effects on absorption or elimination.


Q: Can I stop taking Drossafol suddenly if I feel better?

Official patient information generally includes a statement that stopping the medicine suddenly, particularly when treating a diagnosed deficiency, is not recommended without first consulting a healthcare provider.


Q: Does Drossafol interact with birth control pills?

Official drug interaction lists for Drossafol typically do not include hormonal contraceptives. This indicates that there is no known documented interaction that alters the effectiveness of the birth control pill.


Q: Is Drossafol known to cause weight gain or weight loss?

Weight changes, including both gain or loss, are not listed among the documented and officially reported common or rare adverse reactions for Folic Acid in official regulatory documents.


Q: What is the purpose of Drossafol if I am already taking another similar drug?

Official research and guidelines support the use of Drossafol alongside other standard-of-care medications. This is often done to prevent a deficiency caused by the other medicine, such as certain cancer or anti-inflammatory drugs, or to address a complex underlying cause of the deficiency.


Q: Can Drossafol cause dizziness or make me feel sleepy?

General dizziness or sleepiness are not explicitly listed in the official side effect profile. However, the profile does include Altered sleep patterns and Confusion as central nervous system effects, particularly associated with long-term, high-dose use of the medicine.


Q: Can taking Drossafol affect my ability to drive?

Official regulatory documents typically state that the active ingredient, Folic Acid, has no or negligible influence on the ability to safely drive vehicles and operate machinery.


Q: Is Drossafol available over the counter?

The availability of Folic Acid is based on the dosage strength. Low doses, such as 400 mu g, are widely available without a prescription. However, higher therapeutic doses (e.g., 1 mg or 5 mg) often require a prescription due to the important safety need to screen patients for an underlying Vitamin B12 deficiency.


Q: What happens if I accidentally take two doses of Drossafol?

Folic Acid is generally considered very safe at standard therapeutic levels. Taking two doses at once (an acute overdose) is unlikely to cause serious harm, as official information notes that any excess amount is largely excreted by the kidneys. Any concerns about this event are generally referred to a healthcare professional for guidance.


Q: Does Drossafol affect blood sugar levels?

Changes in blood sugar levels, such as hypoglycemia or hyperglycemia, are not listed among the documented and officially reported common or rare adverse reactions for Folic Acid.


Q: How long after stopping Drossafol do its effects leave the body?

Official pharmacokinetic data indicates that Folic Acid is quickly absorbed, and excess amounts are rapidly cleared by the kidneys. While the compound itself may leave the blood quickly, the beneficial biological effects of correcting a long-standing deficiency may persist until the body’s stored folate is depleted.


Q: Does Drossafol interact with common cold or flu medications?

Official regulatory labels do not list common cold or flu medications, such as standard decongestants or antihistamines, as having documented significant drug-drug interactions with Drossafol.


Q: Why is Drossafol sometimes prescribed with a warning about sun exposure?

Warnings about sun exposure or photosensitivity are not listed among the documented and officially reported adverse reactions for Folic Acid. This means that regulatory documents do not suggest Drossafol increases sensitivity to sunlight.


Q: Can I take Drossafol if I have liver disease?

The liver is the primary organ responsible for converting the inactive Folic Acid into its active form. While official documents may not list liver disease as a direct contraindication, caution is implied in the drug's metabolism profile. Information regarding use in the presence of liver disease is generally evaluated by a healthcare professional.


Q: What is the reason Drossafol is only available by prescription?

Higher therapeutic doses of Drossafol are made available by prescription primarily to ensure patient safety. Prescription status requires that a healthcare professional properly screens the patient for Vitamin B12 deficiency before starting treatment, as Folic Acid can mask the serious neurological progression of this condition.


Q: Can Drossafol be taken by older adults?

Official regulatory eligibility documents state that use is generally permitted for all adults. While there are no specific cautions or restrictions listed solely for the 'older adult' population, this demographic is often subject to individualized considerations due to overall health status.


Q: Are there any specific foods or drinks to avoid while taking Drossafol?

Official warnings specifically mention that chronic alcohol consumption is documented to decrease the absorption and increase the elimination of Folic Acid. Beyond this, regulatory documents do not list specific foods or drinks that must be avoided.


Q: What type of monitoring or tests are usually required while on Drossafol?

Monitoring is critical due to the primary safety risk of masking Vitamin B12 deficiency. Official information requires a full investigation to rule out B12 deficiency before treatment. The duration of treatment for an established deficiency is often monitored until the patient's blood profile normalizes.


Q: Is it necessary to take Drossafol at the exact same time every day?

Official administration guidelines state that the frequency of use is typically 'once-daily.' While the documents emphasize taking the medication regularly to correct a deficiency, they do not explicitly state that taking it at the exact same time every day is a medical necessity for the medicine to work effectively.


Q: What are the signs of a serious allergic reaction to Drossafol?

Official documents list Anaphylactic reactions and Bronchospasm among the rare adverse reactions. These severe reactions involve symptoms like swelling of the face, tongue, or throat, difficulty breathing, and widespread rash. Patients should be aware of these official terms.


Q: Why do doctors sometimes prescribe Drossafol for uses not listed in the main description?

Official research evidence exists concerning the investigation of Drossafol for secondary applications, such as certain chronic pain conditions. While clinical practice involves many considerations, the regulatory information limits the stated indication to what is officially approved.

How should Drossafol be stored and disposed of?

The official storage and disposal instructions for Drossafol (Folic Acid tablets) are defined by government regulatory labeling to ensure product stability and safety.

Required Storage Conditions

Drossafol must be stored at Controlled Room Temperature, specifically between 20^circmathrmC and 25^circmathrmC (68^circmathrmF to 77^circmathrmF). The product must be protected from light and excessive moisture and should be kept in the well-closed container in which it was dispensed.

Child Safety and Disposal

It is mandatory that Drossafol is stored out of the sight and reach of children, and the container must feature a child-resistant closure. For disposal, unused or expired tablets should be managed through an official drug take-back program. If a program is unavailable, the medicine must be disposed of in household trash only after being mixed with an unpalatable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drossafol found in:

A-Z Index: